Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement
- PMID: 8524972
- DOI: 10.1007/BF02311172
Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement
Abstract
ABT-418, a newly characterized centrally acting cholinergic channel activator (ChCA), was evaluated for its ability to improve performance in a delayed matching-to-sample (DMTS) task by mature macaques well trained in the task. Previous studies in rodents have indicated that ABT-418 shares the memory/cognitive enhancing actions of nicotine, but without many of nicotine's dose-limiting side effects. As DMTS provides a measure both of general cognitive function (the matching concept) and of recent memory, it was hypothesized that some doses of ABT-418 would enhance the monkeys' ability to correctly perform the DMTS task. Intramuscular administration of ABT-418 significantly enhanced DMTS performance at low (2-32.4 nmol/kg) doses. In fact, the drug was slightly more potent that nicotine in this regard, and all eight animals tested in this study exhibited enhanced performance at one or more doses. ABT-418 produced the greatest improvement in DMTS performance at the longest delay interval. In animals repeatedly tested with their individualized "Best Dose", DMTS performance increased on average by 10.1 +/- 3.5 percentage points correct, which was equivalent to an increase of 16.2% over baseline performance. ABT-418 did not significantly affect response times, i.e., latencies to make a choice between stimuli, or latencies to initiate new trials. Whereas nicotine enhanced DMTS performance both on the day of administration and on the following day (in the absence of drug), ABT-418-induced enhanced performance was detected only on the day of administration. Finally, single daily administration of the individualized best dose in three monkeys over a period of 8 days generally maintained enhancement of DMTS performance. Thus, the data were not consistent with the development of significant tolerance to the drug's mnemonic actions. In contrast to nicotine, no overt toxicity or side effects to acute or repeated administration of the drug were noted. Thus, ABT-418 represents a prototype of a new class of nicotinic agonists designed for the potential treatment of human dementias having a low profile of toxicity.
Similar articles
-
Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418.Psychopharmacology (Berl). 1997 Apr;130(3):276-84. doi: 10.1007/s002130050240. Psychopharmacology (Berl). 1997. PMID: 9151363
-
Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.Psychopharmacology (Berl). 1998 Mar;136(1):50-8. doi: 10.1007/s002130050538. Psychopharmacology (Berl). 1998. PMID: 9537682
-
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. J Pharmacol Exp Ther. 1994. PMID: 7913497
-
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.CNS Drug Rev. 2004 Summer;10(2):167-82. doi: 10.1111/j.1527-3458.2004.tb00011.x. CNS Drug Rev. 2004. PMID: 15179445 Free PMC article. Review.
-
Neuroregulatory effects of nicotine.Psychoneuroendocrinology. 1989;14(6):407-23. doi: 10.1016/0306-4530(89)90040-1. Psychoneuroendocrinology. 1989. PMID: 2560221 Review.
Cited by
-
Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.CNS Drugs. 2002;16(7):485-500. doi: 10.2165/00023210-200216070-00005. CNS Drugs. 2002. PMID: 12056923
-
Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys.Psychopharmacology (Berl). 2005 Jun;179(4):725-32. doi: 10.1007/s00213-004-2114-1. Epub 2004 Dec 24. Psychopharmacology (Berl). 2005. PMID: 15619109
-
Guidelines on nicotine dose selection for in vivo research.Psychopharmacology (Berl). 2007 Feb;190(3):269-319. doi: 10.1007/s00213-006-0441-0. Epub 2006 Aug 9. Psychopharmacology (Berl). 2007. PMID: 16896961 Review.
-
The antisaccade task as an index of sustained goal activation in working memory: modulation by nicotine.Psychopharmacology (Berl). 2006 Nov;188(4):521-9. doi: 10.1007/s00213-006-0455-7. Epub 2006 Aug 1. Psychopharmacology (Berl). 2006. PMID: 16896958 Clinical Trial.
-
Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.Biochem Pharmacol. 2011 Oct 15;82(8):883-90. doi: 10.1016/j.bcp.2011.06.010. Epub 2011 Jun 12. Biochem Pharmacol. 2011. PMID: 21684265 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials